An Interaction Study to Assess the Effect of the Ezogabine/Retigabine and the Main Metabolite NAMR on the Pharmacokinetics of Digoxin in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Digoxin (Primary) ; Retigabine (Primary)
- Indications Conduction disorders; Epilepsy
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2012 New trial record